within Pharmacolibrary.Drugs.N_NervousSystem.N05C_HypnoticsAndSedatives.N05CD06_Lormetazepam;

model Lormetazepam
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 2.7777777777777776e-07,
    adminDuration = 600,
    adminMass = 2 / 1000000,
    adminCount = 1,
    Vd = 0.085,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.008333333333333333,
    Tlag = 12.0);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Lormetazepam</td></tr><tr><td>ATC code:</td><td>N05CD06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>85</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Lormetazepam is a short-to-intermediate acting benzodiazepine hypnotic used primarily for the short-term management of insomnia. It exerts its effect by enhancing the activity of gamma-aminobutyric acid (GABA) at the GABAA receptor. Lormetazepam is approved in several European countries, but is not currently approved by the FDA in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers, both male and female, aged 20 to 40 years.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05CD06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Lormetazepam;
